BMO Capital Downgrades Novo Nordisk to Market Perform, Lowers Price Target to $64

Benzinga · 04/17/2025 11:01
BMO Capital analyst Evan David Seigerman downgrades Novo Nordisk (NYSE:NVO) from Outperform to Market Perform and lowers the price target from $105 to $64.